Physician profile
Venus Ramos
NPI 1679503940
$761.27
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $28.59 · 2022: $47.14 · 2023: $277 · 2024: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $135.96 | 2023-2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.09 | 2023-2024 | Relistor |
| Genzyme Corporation | $121.83 | 2024 | |
| Acadia Pharmaceuticals INC | $119.51 | 2019 | |
| Merz Pharmaceuticals, LLC | $98.86 | 2022-2024 | Xeomin |
| Collegium Pharmaceutical, INC. | $63.77 | 2023 | Belbuca |
| Abbvie INC. | $39.98 | 2022-2023 | |
| Merz North America, INC. | $28.59 | 2020 | |
| Metacel Pharmaceuticals LLC | $20.68 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venus Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.